List Trials for Newly Diagnosed Castleman’s Disease

Castleman’s Disease


The Castleman's Study (2366)
A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease

Investigator: Corey Casper;   Conditions: Lymphoproliferative Disease;    Status: Closed;   Study ID: NCT01024036